Your trusted source for investing success
By Jocelyn Aspa
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
Major players in the pharmaceutical industry include Johnson & Johnson, Novartis, Roche, Pfizer and Merck.
GT Biopharma announced the appointment of Dr. Raymond Urbanski as their new chief medical officer.
VistaGen Therapeutics announced the appointment of Dr. David Rotella to the scientific advisory board of their subsidiary VistaStem Therapeutics.
Reports have indicated to the growth for the industry based on the curiosity and need for patients to find new therapies involved to their diseases.
Oxis International appoints new CEO and Chief Medical Officer as it completes acquisition of Georgetown Translational Pharmaceuticals.
The pharmaceutical market is only expected to increase in value in the coming years, meaning that there are exciting opportunities for investing in pharmaceutical stocks.
By Pia Rivera
To help make investors aware of some of their options when looking at investing in the pharmaceutical sector, the Investing News Network took a look at the five top pharmaceutical ETFs.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today provided a shareholder update and highlighted the company’s recent achievements it has reached during the first part of
Naturally Splendid (TSXV:NSP) is pleased to announce the Company has entered into an Exclusive Sales Agreement with Laguna Blends Inc.(TSX-V:LAG) to market and distribute a complete line of CBD formulated, cosmeceutical products that will be launched at the SEOUL FOOD & HOTEL tradeshow in May 2017 as an official delegate
Protalix BioTherapeutics announced new encouraging preclinical results for PRX-102 treatment on mice.
Naturally Splendid (TSXV:NSP) is pleased to announce they have entered into a marketing and distribution agreement with First Step Japan (“FSJ”), to market its NATERA® CBD product line in Japan, the world’s third largest economy.
The mutually exclusive relationship between FSJ and NSE involves FSJ representing CBD based products offered by
Naturally Splendid (TSXV:NSP) has provided the following update on its proprietary omega encapsulation technology HempOmega and the addition of Kelley Fitzpatrick to the advisory board.
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, today announced the Company closed a private placement with proceeds of $4,349,953.50. Laidlaw & Co (UK) Ltd. in New
Naturally Splendid (TSXV:NSP) is pleased to announce it will be launching a first to the Canadian retail market, a HempOmega™ fortified protein blend under its NATERA® brand at the Canadian Health Food Association (“CHFA”) West Expo, in Vancouver on April 8th-9th 2017 in Vancouver.
